Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ErascaERAS +1.20%22 Cash-to-Debt is 6.01 as of Jun. 2026, which is 5% below its 10-year median of 6.31. GuruFocus rates ERAS with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,342 Biotechnology companies, Erasca ranks worse than 52.01% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Erasca's cash to debt ratio for the quarter that ended in Jun. 2026 was 6.01.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Erascacould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Erasca's Cash-to-Debt or its related term are showing as below:
ERAS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 5.23 Med: 6.31 Max: 76.57
Current: 6.01
During the past 7 years, Erasca's highest Cash to Debt Ratio was 76.57. The lowest was 5.23. And the median was 6.31.
ERAS's Cash-to-Debt is ranked worse than 52.01% of 1342
companies
in the Biotechnology industry
Industry Median: 7.39
vs ERAS: 6.01
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Erasca Cash-to-Debt Related Terms
Erasca Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Erasca's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Erasca's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Erasca Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Erasca's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Erasca's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca (ERAS) has a Cash-to-Debt of 6.01 as of Jun. 2026. This is near median its historical median of 6.31. Over the past decade, Erasca's Cash-to-Debt has ranged from 5.23 to 76.57. According to the industry distribution chart, Erasca ranks #698 out of 1342 companies in the Biotechnology industry, placing it in the top 52%.
Is Erasca's Cash-to-Debt too high?
Erasca's current Cash-to-Debt of 6.01 is near median its 10-year median of 6.31. Over the past 10 years, this metric has ranged from a low of 5.23 to a high of 76.57. The Biotechnology industry median Cash-to-Debt is 7.39. Erasca's value of 6.01 is 18.7% below this industry median. Based on the distribution chart, Erasca ranks #698 out of 1342 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Erasca has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Erasca's Cash-to-Debt compare to COGT and PTCT?
According to the Biotechnology industry distribution chart, Erasca ranks #698 out of 1342 companies for Cash-to-Debt. This places Erasca in the lower half of its industry. The industry median Cash-to-Debt is 7.39. Erasca's value of 6.01 is 18.7% below this benchmark. Historically, Erasca's own Cash-to-Debt has ranged from 5.23 to 76.57 over the past decade. While the company's 10-year median is 6.31 vs. the industry median of 7.39, Erasca has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.39, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Erasca's current Cash-to-Debt of 6.01 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Erasca's current Cash-to-Debt is 6.01, which is near median its own 10-year median of 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Erasca stock overvalued right now?
Erasca (ERAS) has a current Cash-to-Debt of 6.01. The current Cash-to-Debt is 6.01, which is near median its 10-year median of 6.31 and 18.7% below the Biotechnology industry median of 7.39. Erasca's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Erasca (ERAS), the current Cash-to-Debt is 6.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
22GF Score
Get the complete analysis for ERAS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERAS has been successfully added to your 
